Amicus Therapeutics Commences Phase 3 Trial Evaluating Amigal(TM) for the Treatment of Fab... (t costs on a 50/50 basis and in return S...)

Amicus Therapeutics Commences Phase 3 Trial Evaluating Amigal(TM) for the Treatment of Fabry Disease

Date:6/22/2009

t costs on a 50/50 basis, and in return Shire received rights to commercialize these products outside of the U.S. while Amicus retains all rights to commercialize these products in the U.S. In addition, Amicus leads development operations through the end of Phase 2 clinical trials. The companies then share responsibility for Phase 3 clinical trial development leveraging Shire's significant ex-U.S. regulatory and clinical experience as well as its commercial infrastructure.

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs.

Amicus has a strategic collaboration with Shire Human Genetic Therapies, Inc., a wholly-owned subsidiary of Shire Limited, to develop and commercialize Amicus' three lead pharmacological chaperone compounds for lysosomal storage disorders. Under the agreement, Shire received commercial rights outside of the United States. Amicus retains all U.S. rights.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as, but not limited to, "look forward to," "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," "should" and "could," and similar expressions or words identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances,
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Post Your Comments:

(Date:5/20/2013)... BETHESDA, Md. , May 20, 2013 TNI ... diseases through the activation and mobilization of the body,s ... trading on the OTC Markets, OTCQB marketplace under the ... able to view the real-time Level II stock quotes ... Noreen Griffin , CEO of TNI BioTech, ...

(Date:5/20/2013)... Ill. , May 20, 2013 AbbVie ... initiation of a Phase 3 clinical study called ... assess the effects of the investigational compound atrasentan - ... of kidney disease in patients with stage 2 ... 2 diabetes. SONAR is a large, multinational, double-blind, ...

(Date:5/19/2013)... , May 20, 2013 Whole-cell pertussis vaccines were ... vaccines during a large recent outbreak, according to a ... Whole-cell pertussis vaccines, also called DTwP, were available from ... concerns that ultimately led to the development of acellular ... late 1990s, the United States ...

Breaking Medicine Technology:TNI BioTech, Inc. Stock to Begin Trading on the OTCQB Marketplace 2 TNI BioTech, Inc. Stock to Begin Trading on the OTCQB Marketplace 3 AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 2 AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 3 AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 4 AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 5 AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 6 Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis Outbreak 2 Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis Outbreak 3 Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis Outbreak 4

[0] TNI BioTech, Inc. Stock to Begin Trading on the OTCQB Marketplace [0] AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy [0] Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis Outbreak

... 2012 Covance Inc. (NYSE: CVD ) said ... repurchase of up to $300 million of its outstanding ... approximately 800,000 shares remaining under a previously-announced repurchase authorization ... common stock. Any purchases under this buyback would be ...

... leading medical practice providing specialized infertility treatment since 1986, ... test that will replace daily blood tests needed to ... Boston IVF has proven that the hormone estradiol, traditionally ... in saliva, virtually eliminating the need for daily blood ...

Cached Medicine Technology:Covance Board Authorizes $300 Million Stock Buyback 2 Boston IVF Pioneers World's First Needle-Free Saliva Test Used in Infertility Treatment; Patient Friendly Monitoring Replaces Daily Blood Tests 2 Boston IVF Pioneers World's First Needle-Free Saliva Test Used in Infertility Treatment; Patient Friendly Monitoring Replaces Daily Blood Tests 3

Covance Board Authorizes $300 Million Stock Buyback Boston IVF Pioneers World's First Needle-Free Saliva Test Used in Infertility Treatment; Patient Friendly Monitoring Replaces Daily Blood Tests

(Date:5/20/2013)... from Comfort & Harmony was featured at ... Association (USLCA) May 2nd – 5th. The conference hosted ... , The USLCA annual conference is a trade ... about the latest trends in lactation. , Mombo ... new mothers use to help support infants while breastfeeding. ...

(Date:5/20/2013)... 2013 Mirena IUD lawsuit ... litigation recently established in U.S. District Court, Southern District ... to court records, the litigation’s first Status Conference was ... Plaintiff’s leadership positions were discussed. So far, at ... District of New York, all of which allege that ...

(Date:5/20/2013)... 2013 Co-founder of Atlanta SEO ... keynote speaker at the 5th International INVEST Domaining & ... brings together company representatives and independent individuals from around ... marketing and investments. , The 2013 conference will take ... México from May 20 to 21. A networking city ...

(Date:5/20/2013)... Nearly 20 percent of kidneys that are recovered ... transplant due to factors ranging from scarring in small ... organ going too long without blood or oxygen. But, ... be "recycled" to help solve the critical shortage of ... Center and colleagues, reporting in the journal Biomaterials ...

(Date:5/20/2013)... 2013 Horizon NJ Health, New Jersey’s ... that it has earned a Commendable Accreditation status ... NJ Health is a wholly owned subsidiary of Horizon ... NCQA Health Plan Accreditation is a nationally recognized program ... health plans provide to their members. Health Plan Accreditation ...

Breaking Medicine News(10 mins):Health News:Comfort & Harmony™ Exhibited mombo™ Nursing Pillow at USLCA’s First Inaugural Conference 2 Health News:Mirena IUD Lawsuit News: Bernstein Liebhard LLP Reports on First Status Conference in Federal Mirena Litigation 2 Health News:Mirena IUD Lawsuit News: Bernstein Liebhard LLP Reports on First Status Conference in Federal Mirena Litigation 3 Health News:EverSpark CEO to be Keynote Speaker at 5th International INVEST Domaining & Internet Marketing Conference in Mexico City 2 Health News:Study suggests new source of kidneys for transplant 2 Health News:Horizon NJ Health Awarded Commendable Accreditation by NCQA 2 Health News:Horizon NJ Health Awarded Commendable Accreditation by NCQA 3

[0] Comfort & Harmony™ Exhibited mombo™ Nursing Pillow at USLCA’s First Inaugural Conference [0] Mirena IUD Lawsuit News: Bernstein Liebhard LLP Reports on First Status Conference in Federal Mirena Litigation [0] EverSpark CEO to be Keynote Speaker at 5th International INVEST Domaining & Internet Marketing Conference in Mexico City [0] Study suggests new source of kidneys for transplant [0] Horizon NJ Health Awarded Commendable Accreditation by NCQA

... ST. LOUIS, Nov. 10 KV Pharmaceutical Company,(NYSE: KVa/KVb) ... previously announced, the Company will be delayed in the ... fiscal 2009. The Company expects to,file a Form 12b-25 ... on Wednesday, November 12, 2008., About KV Pharmaceutical ...

... Left-handed pitcher Jon Lester, who,came back from an off-season ... Boston Red Sox in the 2007 World Series, will ... to a Major League Baseball player,who best exemplifies the ... on and off the field., The 24-year-old Tacoma, ...

... analysis of 33 research projects , , MONDAY, Nov. 10 (HealthDay ... as beta blockers has concluded that they are not useful ... using beta blockers for non-coronary surgery may actually increase the ... conducted the study -- known as a meta-analysis -- recommend ...

... cardiopulmonary bypass does not cause short-term neurological problems ... complex heart defects, according to pediatric researchers. The ... showed adverse neurological effects after newborn surgery for ... news for school-aged children who receive surgery for ...

... 10 A Guide to Implementing,GASB 45, a new issue ... how North Carolina local governments are meeting their,obligations to report ... which is based on a survey of the 30 local ... reports that:, -- 88 percent of the ...

... Net Revenue Increased 93.6% to US$146.5 million; Non-GAAP Gross Margins ... ... 10 /Xinhua-PRNewswire-FirstCall/ -- Mindray,Medical International Limited (NYSE: MR ), a ... selected,unaudited financial results for the third quarter and nine months ended,September ...

KV Pharmaceutical to File Form 12b-25 on November 12, 2008 Red Sox Pitcher Jon Lester Wins 2008 Hutch Award(R)Beta Blocker Use Questioned in Non-Heart Surgery No drop in IQ seen after bypass for child heart surgery A Guide to Implementing GASB 45 Mindray Announces 2008 Third Quarter and Nine Months Results

... Keeler Galilean loupes are ideal ... when increased magnification and a large ... loupes are laser aligned, lightweight and ... ,Fixed working distance and superior depth ...

U tip irrigation-aspiration cannual designed for manual removal of 12 oclock cortex. 23 gauge thin wall irrigation and aspiration lines for maximum aspiration capabilities. Polished finish. Overall l...

... pneumatic stools come with five legs ... of 18" to 25" (total vertical ... hard rubber castors. Comfortable, durable and ... vinyl as standard, other colors available ...

Anterior Stromal Puncture Cannula, 25 g. For treatment of recurrent corneal erosion. Overall length 24 mm. 5/box....

Medicine Products:

SuperVu Galilean System Vukich Irrigating-Aspirating Cannula Reliance Stools, Model 5340 Anterior Stromal Puncture Cannula, 25 g